Table 2.

Adverse events at least possibly related to therapy

Event	Any Grade	Grade 1	Grade 2	Grade 3
	number of patients (%)
Gastrointestinal
Abdominal pain	7 (46.6)	6 (40)	1 (6.6)	0
Nausea	6 (40)	6 (40)	0	0
Constipation	4 (26.6)	3 (20)	1 (6.6)	0
Vomiting	3 (20)	2 (13.3)	1 (6.6)	0
Abdominal distention	2 (13.3)	2 (13.3)	0	0
Flatulence	2 (13.3)	2 (13.3)	0	0
Diarrhea	1 (6.6)	1 (6.6)	0	0
Dysgeusia	1 (6.6)	1 (6.6)	0	0
Achalasia	1 (6.6)	0	0	1 (6.6)
Hepatic
Alkaline phosphatase increased	6 (40)	4 (26.6)	2 (13.3)	0
Bilirubin increased	3 (20)	1 (6.6)	2 (13.3)	0
ALT increased	2 (13.3)	2 (13.3)	0	0
AST increased	2 (13.3)	2 (13.3)	0	0
Hematologic
Platelet count decreased	2 (13.3)	1 (6.6)	1 (6.6)	0
Neutrophil count decreased	2 (13.3)	0	2 (13.3)	0
White blood cells decreased	2 (13.3)	2 (13.3)	0	0
Lymphocyte count decreased	1 (6.6)	0	1 (6.6)	0
Pulmonary
Cough	1 (6.6)	1 (6.6)	0	0
Constitutional
Fatigue	8 (53.3)	7 (46.6)	1 (6.6)	0
Rash	2 (13.3)	2 (13.3)	0	0
Pruritis	2 (13.3)	1 (6.6)	1 (6.6)	0
Dizziness	1 (6.6)	1 (6.6)	0	0
Dry mouth	1 (6.6)	1 (6.6)	0	0
Dry skin	1 (6.6)	1 (6.6)	0	0
Edema	1 (6.6)	1 (6.6)	0	0
Weight loss	1 (6.6)	1 (6.6)	0	0
Neurological
Headache	2 (13.3)	2 (13.3)	0	0
Renal
Hypomagnesemia	1 (6.6)	1 (6.6)	0	0

AEs were graded using the NIC Common Terminology for Adverse Events (Version 4.1)